Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 556

1.

A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes.

Lode HE, Gjølberg TT, Foss S, Sivertsen MS, Brustugun J, Andersson Y, Jørstad ØK, Moe MC, Andersen JT.

Sci Rep. 2019 Dec 2;9(1):18021. doi: 10.1038/s41598-019-54226-7.

2.

Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2.

Troschke-Meurer S, Siebert N, Marx M, Zumpe M, Ehlert K, Mutschlechner O, Loibner H, Ladenstein R, Lode HN.

Oncoimmunology. 2019 Sep 8;8(12):1661194. doi: 10.1080/2162402X.2019.1661194. eCollection 2019.

3.

Neuroblastoma with intracerebral metastases and the need for neurosurgery: a single-center experience.

Fleck S, Marx S, Bobak C, Richter V, Nowak S, Rafaee EE, Siebert N, Ehlert K, Schroeder HWS, Lode HN.

J Neurosurg Pediatr. 2019 Oct 11:1-6. doi: 10.3171/2019.7.PEDS19143. [Epub ahead of print]

PMID:
31604318
4.

Management of tumor rupture and abdominal compartment syndrome in an infant with bilateral high risk stage 4 neuroblastoma: A case report.

Lode HN, Henze G, Siebert N, Ehlert K, Barthlen W.

Medicine (Baltimore). 2019 Aug;98(34):e16752. doi: 10.1097/MD.0000000000016752.

5.

Complement C4 Prevents Viral Infection through Capsid Inactivation.

Bottermann M, Foss S, Caddy SL, Clift D, van Tienen LM, Vaysburd M, Cruickshank J, O'Connell K, Clark J, Mayes K, Higginson K, Lode HE, McAdam MB, Sandlie I, Andersen JT, James LC.

Cell Host Microbe. 2019 Apr 10;25(4):617-629.e7. doi: 10.1016/j.chom.2019.02.016. Epub 2019 Mar 26.

6.

EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells.

Kailayangiri S, Altvater B, Lesch S, Balbach S, Göttlich C, Kühnemundt J, Mikesch JH, Schelhaas S, Jamitzky S, Meltzer J, Farwick N, Greune L, Fluegge M, Kerl K, Lode HN, Siebert N, Müller I, Walles H, Hartmann W, Rossig C.

Mol Ther. 2019 May 8;27(5):933-946. doi: 10.1016/j.ymthe.2019.02.014. Epub 2019 Feb 23.

PMID:
30879952
7.

Co-expression of IL-15 enhances anti-neuroblastoma effectivity of a tyrosine hydroxylase-directed DNA vaccination in mice.

Marx M, Zumpe M, Troschke-Meurer S, Shah D, Lode HN, Siebert N.

PLoS One. 2018 Nov 19;13(11):e0207320. doi: 10.1371/journal.pone.0207320. eCollection 2018.

8.

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.

Ladenstein R, Pötschger U, Valteau-Couanet D, Luksch R, Castel V, Yaniv I, Laureys G, Brock P, Michon JM, Owens C, Trahair T, Chan GCF, Ruud E, Schroeder H, Beck Popovic M, Schreier G, Loibner H, Ambros P, Holmes K, Castellani MR, Gaze MN, Garaventa A, Pearson ADJ, Lode HN.

Lancet Oncol. 2018 Dec;19(12):1617-1629. doi: 10.1016/S1470-2045(18)30578-3. Epub 2018 Nov 12.

PMID:
30442501
9.

Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial.

Siebert N, Troschke-Meurer S, Marx M, Zumpe M, Ehlert K, Gray J, Garaventa A, Manzitti C, Ash S, Klingebiel T, Beck J, Castel V, Valteau-Couanet D, Loibner H, Ladenstein R, Lode HN.

Cancers (Basel). 2018 Oct 17;10(10). pii: E387. doi: 10.3390/cancers10100387.

10.

Inflammatory response and treatment tolerance of long-term infusion of the anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma.

Ceylan K, Jahns LJ, Lode BN, Ehlert K, Kietz S, Troschke-Meurer S, Siebert N, Lode HN.

Pediatr Blood Cancer. 2018 Jun;65(6):e26967. doi: 10.1002/pbc.26967. Epub 2018 Jan 19.

PMID:
29350486
11.

Haploidentical Stem Cell Transplantation for Refractory/Relapsed Neuroblastoma.

Illhardt T, Toporski J, Feuchtinger T, Turkiewicz D, Teltschik HM, Ebinger M, Schwarze CP, Holzer U, Lode HN, Albert MH, Gruhn B, Urban C, Dykes JH, Teuffel O, Schumm M, Handgretinger R, Lang P.

Biol Blood Marrow Transplant. 2018 May;24(5):1005-1012. doi: 10.1016/j.bbmt.2017.12.805. Epub 2018 Jan 4.

12.

Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma.

Lodrini M, Sprüssel A, Astrahantseff K, Tiburtius D, Konschak R, Lode HN, Fischer M, Keilholz U, Eggert A, Deubzer HE.

Oncotarget. 2017 Jul 7;8(49):85234-85251. doi: 10.18632/oncotarget.19076. eCollection 2017 Oct 17.

13.

PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO.

Siebert N, Zumpe M, Jüttner M, Troschke-Meurer S, Lode HN.

Oncoimmunology. 2017 Jul 5;6(10):e1343775. doi: 10.1080/2162402X.2017.1343775. eCollection 2017.

14.

Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO.

Mueller I, Ehlert K, Endres S, Pill L, Siebert N, Kietz S, Brock P, Garaventa A, Valteau-Couanet D, Janzek E, Hosten N, Zinke A, Barthlen W, Varol E, Loibner H, Ladenstein R, Lode HN.

MAbs. 2018 Jan;10(1):55-61. doi: 10.1080/19420862.2017.1402997. Epub 2017 Dec 5.

15.

Individualized risk assessment in neuroblastoma: does the tumoral metabolic activity on 123I-MIBG SPECT predict the outcome?

Rogasch JMM, Hundsdoerfer P, Furth C, Wedel F, Hofheinz F, Krüger PC, Lode H, Brenner W, Eggert A, Amthauer H, Schatka I.

Eur J Nucl Med Mol Imaging. 2017 Dec;44(13):2203-2212. doi: 10.1007/s00259-017-3786-1. Epub 2017 Aug 14.

PMID:
28808732
16.

Call for a European Paediatric Association/Union of National European Paediatric Societies and Associations Survey on National Child Health Care Services for European Children with Malignancies.

Gaedicke G, Gronau W, Lode H, Ehrich J.

J Pediatr. 2017 Oct;189:243-244. doi: 10.1016/j.jpeds.2017.06.047. Epub 2017 Jul 11. Review. No abstract available.

PMID:
28709632
17.

2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors.

Simon T, Hero B, Schulte JH, Deubzer H, Hundsdoerfer P, von Schweinitz D, Fuchs J, Schmidt M, Prasad V, Krug B, Timmermann B, Leuschner I, Fischer M, Langer T, Astrahantseff K, Berthold F, Lode H, Eggert A.

Klin Padiatr. 2017 May;229(3):147-167. doi: 10.1055/s-0043-103086. Epub 2017 May 30.

PMID:
28561228
18.

Corrigendum: Antibody-antigen kinetics constrain intracellular humoral immunity.

Bottermann M, Lode HE, Watkinson RE, Foss S, Sandlie I, Andersen JT, James LC.

Sci Rep. 2017 Apr 6;7:45418. doi: 10.1038/srep45418. No abstract available.

19.

Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells.

Tivnan A, Heilinger T, Ramsey JM, O'Connor G, Pokorny JL, Sarkaria JN, Stringer BW, Day BW, Boyd AW, Kim EL, Lode HN, Cryan SA, Prehn JH.

Oncotarget. 2017 Mar 7;8(10):16605-16620. doi: 10.18632/oncotarget.15073.

20.

Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival.

Siebert N, Jensen C, Troschke-Meurer S, Zumpe M, Jüttner M, Ehlert K, Kietz S, Müller I, Lode HN.

Oncoimmunology. 2016 Sep 26;5(11):e1235108. doi: 10.1080/2162402X.2016.1235108. eCollection 2016.

21.

Antibody-antigen kinetics constrain intracellular humoral immunity.

Bottermann M, Lode HE, Watkinson RE, Foss S, Sandlie I, Andersen JT, James LC.

Sci Rep. 2016 Nov 24;6:37457. doi: 10.1038/srep37457. Erratum in: Sci Rep. 2017 Apr 06;7:45418.

22.

GM-CSF as successful salvage therapy of metamizole (dipyrone)-induced agranulocytosis with Fournier's gangrene and severe septic shock in an adolescent.

Winkler A, Kietz S, Bahlmann H, Jafarzade G, Lode HN, Heckmann M.

Clin Case Rep. 2016 Jul 20;4(8):816-9. doi: 10.1002/ccr3.616. eCollection 2016 Aug.

23.

The impact of socioeconomic factors on the efficiency of voluntary toxoplasmosis screening during pregnancy: a population-based study.

Lange AE, Thyrian JR, Wetzka S, Flessa S, Hoffmann W, Zygmunt M, Fusch C, Lode HN, Heckmann M.

BMC Pregnancy Childbirth. 2016 Jul 29;16(1):197. doi: 10.1186/s12884-016-0966-0.

24.

MYCN-targeting vaccines and immunotherapeutics.

Schramm A, Lode H.

Hum Vaccin Immunother. 2016 Sep;12(9):2257-8. doi: 10.1080/21645515.2016.1171430. Epub 2016 Apr 20.

25.

Generation and Characterization of a Human/Mouse Chimeric GD2-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma.

Eger C, Siebert N, Seidel D, Zumpe M, Jüttner M, Brandt S, Müller HP, Lode HN.

PLoS One. 2016 Mar 11;11(3):e0150479. doi: 10.1371/journal.pone.0150479. eCollection 2016.

26.

Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2.

Siebert N, Eger C, Seidel D, Jüttner M, Zumpe M, Wegner D, Kietz S, Ehlert K, Veal GJ, Siegmund W, Weiss M, Loibner H, Ladenstein R, Lode HN.

MAbs. 2016;8(3):604-16. doi: 10.1080/19420862.2015.1130196. Epub 2016 Jan 19.

27.

Targeting of heme oxygenase-1 as a novel immune regulator of neuroblastoma.

Fest S, Soldati R, Christiansen NM, Zenclussen ML, Kilz J, Berger E, Starke S, Lode HN, Engel C, Zenclussen AC, Christiansen H.

Int J Cancer. 2016 Apr 15;138(8):2030-42. doi: 10.1002/ijc.29933. Epub 2015 Dec 12.

28.

[Vaccinations in respiratory medicine].

Lode HM, Stahlmann R.

HNO. 2015 Sep;63(9):649-59; quiz 659-60. doi: 10.1007/s00106-015-0058-x. German.

PMID:
26330051
29.

Mutational dynamics between primary and relapse neuroblastomas.

Schramm A, Köster J, Assenov Y, Althoff K, Peifer M, Mahlow E, Odersky A, Beisser D, Ernst C, Henssen AG, Stephan H, Schröder C, Heukamp L, Engesser A, Kahlert Y, Theissen J, Hero B, Roels F, Altmüller J, Nürnberg P, Astrahantseff K, Gloeckner C, De Preter K, Plass C, Lee S, Lode HN, Henrich KO, Gartlgruber M, Speleman F, Schmezer P, Westermann F, Rahmann S, Fischer M, Eggert A, Schulte JH.

Nat Genet. 2015 Aug;47(8):872-7. doi: 10.1038/ng.3349. Epub 2015 Jun 29.

PMID:
26121086
30.

Targeting of MYCN by means of DNA vaccination is effective against neuroblastoma in mice.

Stermann A, Huebener N, Seidel D, Fest S, Eschenburg G, Stauder M, Schramm A, Eggert A, Lode HN.

Cancer Immunol Immunother. 2015 Oct;64(10):1215-27. doi: 10.1007/s00262-015-1733-1. Epub 2015 Jun 16.

PMID:
26076666
31.

Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.

Seidel D, Shibina A, Siebert N, Wels WS, Reynolds CP, Huebener N, Lode HN.

Cancer Immunol Immunother. 2015 May;64(5):621-34. doi: 10.1007/s00262-015-1669-5. Epub 2015 Feb 25.

PMID:
25711293
32.

[Pharmacokinetics of antibiotics in obese and critical care patients].

Stahlmann R, Lode H.

Dtsch Med Wochenschr. 2015 Feb;140(4):271-6. doi: 10.1055/s-0041-100443. Epub 2015 Feb 19. Review. German.

PMID:
25704524
33.

Febrile ulceronecrotic Mucha-Habermann disease following suspected hemorrhagic chickenpox infection in a 20-month-old boy.

Lode HN, Döring P, Lauenstein P, Hoeger P, Dombrowski F, Bruns R.

Infection. 2015 Oct;43(5):583-8. doi: 10.1007/s15010-015-0726-5. Epub 2015 Jan 28.

PMID:
25627543
34.

The clinical positioning of telavancin in Europe.

Masterton R, Cornaglia G, Courvalin P, Lode HM, Rello J, Torres A.

Int J Antimicrob Agents. 2015 Mar;45(3):213-20. doi: 10.1016/j.ijantimicag.2014.12.006. Epub 2014 Dec 24. Review.

PMID:
25600892
35.

Functional bioassays for immune monitoring of high-risk neuroblastoma patients treated with ch14.18/CHO anti-GD2 antibody.

Siebert N, Seidel D, Eger C, Jüttner M, Lode HN.

PLoS One. 2014 Sep 16;9(9):e107692. doi: 10.1371/journal.pone.0107692. eCollection 2014.

36.

Preserving the efficacy of front-line fluoroquinolones through selective use to optimise clinical outcomes.

Lode HM.

Int J Antimicrob Agents. 2014 Jun;43(6):497-507. doi: 10.1016/j.ijantimicag.2014.02.014. Epub 2014 Apr 8. Review.

PMID:
24787481
37.

Validated detection of human anti-chimeric immune responses in serum of neuroblastoma patients treated with ch14.18/CHO.

Siebert N, Eger C, Seidel D, Jüttner M, Lode HN.

J Immunol Methods. 2014 May;407:108-15. doi: 10.1016/j.jim.2014.04.001. Epub 2014 Apr 12.

PMID:
24727144
38.

Development of immunomonitoring of antibody‑dependent cellular cytotoxicity against neuroblastoma cells using whole blood.

Chowdhury F, Lode HN, Cragg MS, Glennie MJ, Gray JC.

Cancer Immunol Immunother. 2014 Jun;63(6):559-69.

PMID:
24658837
39.

Regional advisory board position statement on optimal pneumococcal vaccination in adults. Update to 2011 consensus on adult pneumococcal disease: update on optimal pneumococcal vaccination in adults.

Ludwig E, Unal S, Bogdan M, Chlíbek R, Ivanov Y, Kozlov R, Lode H, Mészner Z, Prymula R, Rahav G, Skoczyńska A, Solovic I, Sayiner A.

Cent Eur J Public Health. 2013 Dec;21(4):233-6.

40.

Chronic diseases in pregnant women: prevalence and birth outcomes based on the SNiP-study.

Kersten I, Lange AE, Haas JP, Fusch C, Lode H, Hoffmann W, Thyrian JR.

BMC Pregnancy Childbirth. 2014 Feb 19;14:75. doi: 10.1186/1471-2393-14-75.

41.

[Incidence and duration of therapy of pathological hip findings in U2 and U3 examinations (SNiP study)].

Lange A, Lange J, Thyrian R, Haas JP, Ekkernkamp A, Merk H, Hoffmann W, Lode HN.

Orthopade. 2014 Feb;43(2):129-35. doi: 10.1007/s00132-013-2200-3. German.

PMID:
24464331
42.

[Multiresistant pathogens--a challenge for clinicians].

Lode HM, Stahlmann R, Kresken M.

Zentralbl Chir. 2013 Oct;138(5):549-53. doi: 10.1055/s-0033-1350885. Epub 2013 Oct 22. Review. German.

PMID:
24150804
43.

Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab.

Siebert N, Seidel D, Eger C, Brackrock D, Reker D, Schmidt M, Lode HN.

J Immunol Methods. 2013 Dec 15;398-399:51-9. doi: 10.1016/j.jim.2013.09.008. Epub 2013 Sep 18.

PMID:
24055592
44.

Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 study.

Ladenstein R, Weixler S, Baykan B, Bleeke M, Kunert R, Katinger D, Pribill I, Glander P, Bauer S, Pistoia V, Michon J, Garaventa A, Lode HN.

MAbs. 2013 Sep-Oct;5(5):801-9. doi: 10.4161/mabs.25215. Epub 2013 May 31.

45.

[Progress with management of hereditary angioedema].

Johnston DT, Lode H.

MMW Fortschr Med. 2013 Mar 21;155 Suppl 1:1-5. Review. German.

PMID:
23678665
46.

Risks associated with the therapeutic use of fluoroquinolones.

Stahlmann R, Lode HM.

Expert Opin Drug Saf. 2013 Jul;12(4):497-505. doi: 10.1517/14740338.2013.796362. Epub 2013 May 7. Review.

PMID:
23651367
47.
48.

Vaccination with anti-idiotype antibody ganglidiomab mediates a GD(2)-specific anti-neuroblastoma immune response.

Lode HN, Schmidt M, Seidel D, Huebener N, Brackrock D, Bleeke M, Reker D, Brandt S, Mueller HP, Helm C, Siebert N.

Cancer Immunol Immunother. 2013 Jun;62(6):999-1010. doi: 10.1007/s00262-013-1413-y. Epub 2013 Apr 17.

PMID:
23591980
49.

Spontaneous vesicoureteral reflux resolution in children: A ten-year single-centre experience.

Wildbrett P, Schwebs M, Abel JR, Lode H, Barthlen W.

Afr J Paediatr Surg. 2013 Jan-Apr;10(1):9-12. doi: 10.4103/0189-6725.109375.

50.

Salmonella SL7207 application is the most effective DNA vaccine delivery method for successful tumor eradication in a murine model for neuroblastoma.

Berger E, Soldati R, Huebener N, Hohn O, Stermann A, Durmus T, Lobitz S, Zenclussen AC, Christiansen H, Lode HN, Fest S.

Cancer Lett. 2013 May 1;331(2):167-73. doi: 10.1016/j.canlet.2012.12.026. Epub 2013 Jan 18.

PMID:
23337288

Supplemental Content

Support Center